Previous 10 | Next 10 |
Bellerophon Therapeutics (NASDAQ: BLPH ) +472% on FDA nod for emergency use of INOpulse for Covid-19. More news on: Bellerophon Therapeutics, Inc., Rand Capital, GenMark Diagnostics, Inc., Stocks on the move, Read more ...
Mylan N.V. ( MYL +6% ) has restarted production of hydroxychloroquine sulfate tablets at its West Virginia facility in order to meet COVID-19-related demand, although it is not formerly approved for this use (currently authorized to treat malaria, lupus erythematosus and rheumatoid arthr...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has appointed Tasos Konidaris as Senior Vice President, Chief Financial Officer, effective March 12, 2020. Mr. Konidaris succeeds Todd Branning, who is no longer serving in thi...
Image source: The Motley Fool. Amneal Pharmaceuticals, Inc. (NYSE: AMRX) Q4 2019 Earnings Call Feb 26, 2020 , 8:30 a.m. ET Operator Continue reading
Amneal Pharmaceuticals Inc. (AMRX) Q4 2019 Earnings Conference Call February 26, 2020 8:30 AM ET Company Participants Steve Manzano - General Counsel and Corporate Secretary Chirag Patel - Co Chief Executive Officer and President Chintu Patel - Co Chief Executive Officer Todd B...
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2019 Q4 earnings Read more ...
Amneal Pharmaceuticals (NYSE: AMRX ): Q4 Non-GAAP EPS of $0.08 beats by $0.03 ; GAAP EPS of -$0.23 misses by $0.15 . More news on: Amneal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
‒ Q4 2019 Net Revenue of $397 million; GAAP Loss per share of ($0.23); Net Loss of ($32 million) ‒ ‒ Q4 2019 Adjusted EBITDA (1) of $81 million; Adjusted Diluted EPS (1) of $0.08 ‒ ‒ Full Year Net Revenue of $1.63 billion; GAAP Loss per sh...
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) announced today that the Company will release its fourth quarter and full year 2019 financial results on Wednesday, February 26, 2020, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the in...
Gainers: NAVI +6.4% . NNVC +5.7%. IBM +4.3% . EXPR +4.1% . SPCE +3.1% . More news on: Navient Corporation, NanoViricides, Inc., International Business Machines Corporation, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...